Psoriasis – US Drug Forecast and Market Analysis to 2024

Date: 2016-08

Psoriasis – US Drug Forecast and Market Analysis to 2024


Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the Psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-17 (IL-17) inhibitors (Cosentyx, guselkumab and tildrakizumab), interleukin-23 (IL-23) inhibitors (ixekizumab and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developmentsof biosimilars are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

The US is the largest psoriasis market, although it does not have the highest diagnosed prevalence rates of psoriasis. The US will experience major brand erosion beginning with Humira in 2016, followed by Remicade in 2018 and Stelara in 2023; Enbrel is protected until 2028. Biosimilars are likely to launch in 2016 for adalimumab and will take some patient share away from Humira. Although biosimilar uptake will be favored for its cost effectiveness, unclear requirements for demonstrating interchangeability with originator biologics, as well as strong preferences for originator products among dermatologists, could be hindering factors.

*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.


– Overview of Psoriasis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
– Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
– Sales forecast for the top drugs in the US from 2014-2024.
– Analysis of the impact of key events as well the drivers and restraints affecting the US Psoriasis market.

Reasons to buy

– Understand and capitalize by identifying products that are most likely to ensure a robust return
– Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis.
– Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
– Make more informed business decisions from insightful and in-depth analysis of drug performance
– Obtain sales forecast for drugs from 2014-2024 in US.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample